Skip to main content

Do GLP-1 drugs like Ozempic or Wegovy affect bone density?

Medically reviewed by Kristianne Hannemann, PharmD. Last updated on Sep 10, 2025.

Official Answer by Drugs.com

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as Ozempic (semaglutide) and Wegovy (semaglutide), are widely used for treating type 2 diabetes and weight loss. Recent studies highlight potential risks to bone mineral density (BMD) and fracture risk, particularly in specific patient populations. Incorporating a regular exercise routine can help mitigate potential bone loss from GLP-1 drugs due to rapid weight loss.

How Do GLP-1 Drugs Affect Bone Density?

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including Ozempic, Wegovy, and Mounjaro, interact with the body's bone metabolism in complex ways. These medications act on receptors in both osteoblasts (which build bone) and osteoclasts (which break bone down), potentially tipping the balance between bone formation and resorption.

GLP-1 drugs influence bone metabolism through receptors in bone-forming osteoblasts and bone-resorbing osteoclasts:

These drugs also affect bone health indirectly:

Research is ongoing to study the effects of GLP-1 drugs on bone development in adolescents. There is concern about whether patients in this age group taking GLP-1 drugs might not get enough nutrition due to a decreased appetite, which could impact bone health.

What Does Research Say About GLP-1 Drugs and Bone Health?

Recent large studies provide reassurance about fracture risk and bone mineral density with GLP-1 receptor agonists in people with type 2 diabetes; meta-analyses have shown a neutral or lower risk of fracture compared to other diabetes therapies.

Related questions

How to Support Bone Health with GLP-1 Therapy

For people using GLP-1 drugs such as Ozempic, Wegovy, or Mounjaro—especially those at risk for osteoporosis—there are evidence-based steps to preserve bone density:

Summary

GLP-1 drugs appear to have a neutral to minimal impact on bone health. However, rapid weight loss can contribute to bone loss. Incorporating regular exercise may help preserve bone density during treatment. If you have concerns about bone health while taking GLP-1 medications, consult your healthcare provider.

References
  1. Chen, M., Lyu, Y., Zhao, J., Han, X., Huang, T., Yang, T., & Zhou, Y. (2025). Use of GLP-1 receptor agonist and risk of osteoporosis among patients with type 2 diabetes: a real-world study. Frontiers in endocrinology, 16, 1586589. https://doi.org/10.3389/fendo.2025.1586589
  2. Daniilopoulou, I., et. al. 2022. The Impact of GLP1 Agonists on Bone Metabolism: A Systematic Review. In: Medicina. DOI: https://doi.org/10.3390/medicina58020224
  3. Hansen, M. S., Wölfel, E. M., Jeromdesella, S., Møller, J. K., Ejersted, C., Jørgensen, N. R., Eastell, R., Hansen, S. G., & Frost, M. (2024). Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial. EClinicalMedicine, 72, 102624. https://doi.org/10.1016/j.eclinm.2024.102624
  4. Iepsen, E. W., et. al. 2015. GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women, The Journal of Clinical Endocrinology & Metabolism, Volume 100, Issue 8, 1 August 2015, Pages 2909–2917, https://doi.org/10.1210/jc.2015-1176
  5. Jensen, S. B. K., et al. 2024. Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment: A Secondary Analysis of a Randomized Clinical Trial. In: JAMA. DOI: https://doi.org/10.1001/jamanetworkopen.2024.16775
  6. UCI Health. 2024. GLP-1 weight loss drugs can affect bone development in adolescents. Accessed 02/24/2025 at https://www.ucihealth.org/news/2024/12/ozempic-bone-health
  7. Xie, B., et. al. 2021. The Impact of Glucagon-Like Peptide 1 Receptor Agonists on Bone Metabolism and Its Possible Mechanisms in Osteoporosis Treatment. In: Frontiers. DOI: https://doi.org/10.3389/fphar.2021.697442
  8. Zhang, Y. S., et. al. 2018. Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials. In: Osteoporosis International. DOI: https://doi.org/10.1007/s00198-018-4649-8
  9. Zhao, C., Liang, J., Yang, Y., Yu, M., & Qu, X. (2017). The Impact of Glucagon-Like Peptide-1 on Bone Metabolism and Its Possible Mechanisms. Frontiers in endocrinology, 8, 98. https://doi.org/10.3389/fendo.2017.00098

Read next

Ozempic Mounjaro Wegovy & Zepbound: Weight Loss Compared

Ozempic, Mounjaro, Wegovy and Zepbound can all lead to long-term weight loss, but only Wegovy and Zepbound are approved by the FDA for this use. In studies, Zepbound has led to a 21% weight loss in adults using the highest dose, while Wegovy has led to about a 15% weight loss.

Continue reading

Wegovy vs Ozempic: Which is Right for You?

Both Wegovy and Ozempic contain semaglutide, but Wegovy is prescribed for long-term weight management while Ozempic is used to control blood sugar levels in type 2 diabetes and help protect kidney function. They both lower the risk for heart-related complications, but they differ in other approved uses, doses, target populations and costs.

Continue reading

How long does it take for Ozempic to work?

Your blood glucose (sugar) levels should start to fully decline within the first week after you start using Ozempic (semaglutide) at your regular dose. However, the full effect can take 8 weeks or longer, as this is a long-acting medication that is injected only once per week. Continue reading

See also:

Related medical questions

Drug information

Related support groups